» Articles » PMID: 30133504

Risk Factors for Mortality Among Adults Registered on the Routine Drug Resistant Tuberculosis Reporting Database in the Eastern Cape Province, South Africa, 2011 to 2013

Overview
Journal PLoS One
Date 2018 Aug 23
PMID 30133504
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: South Africa is among countries with the highest burden of drug resistant tuberculosis (DR-TB). The Eastern Cape Province reported the highest MDR-TB mortality rates in South Africa for the 2010 treatment cohorts. This study aimed to determine risk factors for mortality among adult patients registered for DR-TB treatment in the province.

Methods: We conducted a retrospective cohort study of adult patients treated for laboratory confirmed DR-TB between January 2011 and December 2013. Demographic and clinical characteristics of the patients were obtained from a web-based electronic database of patients treated for DR-TB. We applied modified Poisson regression with robust standard errors to identify risk factors for DR-TB mortality. We also stratified the analyses into multi-drug resistant TB (MDR-TB) and extensively drug resistant (XDR-TB).

Results: Among 3,729 patients that met the inclusion criteria, 39% (n = 1,445) died. Of the patients that died, 53% (n = 766) were male, 68% (n = 982) had MDR-TB, 72% (n = 1,038) were HIV co-infected, and median age was 37 years (Interquartile Range [IQR] 30-46). Patients were at higher risk of mortality during DR-TB treatment if they were HIV co-infected not on antiretroviral treatment (ART) (adjusted incidence risk ratio [aIRR] 3.3, 95% confidence interval [CI] 2.9-3.8), were 60 years or older (aIRR 1.7, 95%CI 1.5-2.0), had a diagnosis of XDR-TB (aIRR 1.6, 95%CI 1.5-1.7), or had been hospitalised at treatment start (aIRR 1.7, 95%CI 1.5-1.8). Among MDR-TB patients, risk of mortality was higher if patients were HIV co-infected not on ART (aIRR 3.9, 95%CI 3.3-4.6), were 60 years or older (aIRR 1.9, 95%CI 1.6-2.3), or had been hospitalised at start of MDR-TB treatment (aIRR 1.7, 95%CI 1.5-1.9). Among XDR-TB patients, risk of mortality was higher in patients who were HIV co-infected not on ART (aIRR 1.8, 95%CI 1.5-2.2), or had been hospitalised at the start of XDR-TB treatment (aIRR 1.5, 95%CI 1.3-1.8).

Conclusion: HIV co-infected not on ART, older age, XDR-TB and hospital admission for DR-TB treatment were independent risk factors for DR-TB mortality. Integration of TB and HIV services, with focus on voluntary HIV testing and counselling of DR-TB patients with unknown HIV status, and provision of ART for all co-infected patients may reduce DR-TB mortality in the Eastern Cape.

Citing Articles

Determinants of unsuccessful tuberculosis treatment outcome in Southwest Ethiopia regional state public hospitals, 2022: a multi-center case control study.

Berihe Hiluf S, Abera A, Bahiru M, Kassie B Front Public Health. 2024; 12:1406211.

PMID: 39502821 PMC: 11534863. DOI: 10.3389/fpubh.2024.1406211.


Factors associated with mortality among laboratory-diagnosed drug-resistant tuberculosis patients on treatment, KwaZulu-Natal Province, 2017-2019.

Phafane M, Ngozo J, Radebe Z, Lutge E, Ebonwu J Pan Afr Med J. 2024; 47:181.

PMID: 39092023 PMC: 11293477. DOI: 10.11604/pamj.2024.47.181.34571.


Barriers and Enablers to Retention in HIV Care and Adherence to Antiretroviral Therapy: Evidence from Dar es Salaam, Tanzania.

Sambayi G, Bwire G, Kilapilo M, Myemba D, Mosha I, Kilonzi M HIV AIDS (Auckl). 2024; 16:301-311.

PMID: 39081498 PMC: 11288357. DOI: 10.2147/HIV.S458545.


The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia.

Chanda E BMC Infect Dis. 2024; 24(1):364.

PMID: 38556907 PMC: 10983631. DOI: 10.1186/s12879-024-09238-8.


Predictors of Death in Rifampicin Resistant Tuberculosis Patients Treated with the Short Course in Conakry, Guinea.

Bangoura S, Diallo B, Diaby M, Camara A, Hounmenou C, Magassouba A Am J Trop Med Hyg. 2023; 110(1):117-122.

PMID: 37956449 PMC: 10793011. DOI: 10.4269/ajtmh.23-0190.


References
1.
Falzon D, Le Strat Y, Belghiti F, Infuso A . Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tuberc Lung Dis. 2005; 9(11):1224-9. View

2.
Abuaku B, Tan H, Li X, Chen M, Huang X . Treatment default and death among tuberculosis patients in Hunan, China. Scand J Infect Dis. 2010; 42(4):281-7. DOI: 10.3109/00365540903493723. View

3.
Kvasnovsky C, Cegielski J, Erasmus R, Siwisa N, Thomas K, van der Walt M . Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011; 57(2):146-52. DOI: 10.1097/QAI.0b013e31821190a3. View

4.
Quy H, Cobelens F, Lan N, Buu T, Lambregts C, Borgdorff M . Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 2006; 10(1):45-51. View

5.
Farley J, Ram M, Pan W, Waldman S, Cassell G, Chaisson R . Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011; 6(7):e20436. PMC: 3142109. DOI: 10.1371/journal.pone.0020436. View